ATE544354T1 - Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen - Google Patents

Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen

Info

Publication number: ATE544354T1
Authority: AT; Austria
Prior art keywords: methods; polyethylene glycol; gut; molecular weight; high molecular
Prior art date: 2002-11-26

Application number

AT02789898T

Other languages

English (en)

Inventor

John Alverdy

Original Assignee

Univ Chicago

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-26

Filing date

2002-11-26

Publication date

2012-02-15

2002-11-26 Application filed by Univ Chicago filed Critical Univ Chicago

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE544354T1 publication Critical patent/ATE544354T1/de

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
201000010099 disease Diseases 0.000 title abstract 2
230000002265 prevention Effects 0.000 title 1
238000000034 method Methods 0.000 abstract 4
229920001223 polyethylene glycol Polymers 0.000 abstract 4
206010040047 Sepsis Diseases 0.000 abstract 3
239000004705 High-molecular-weight polyethylene Substances 0.000 abstract 2
239000002202 Polyethylene glycol Substances 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
229920002307 Dextran Polymers 0.000 abstract 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
229930182816 L-glutamine Natural products 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
241000589517 Pseudomonas aeruginosa Species 0.000 abstract 1
229920000249 biocompatible polymer Polymers 0.000 abstract 1
235000013350 formula milk Nutrition 0.000 abstract 1
244000000074 intestinal pathogen Species 0.000 abstract 1
238000012544 monitoring process Methods 0.000 abstract 1
235000015097 nutrients Nutrition 0.000 abstract 1
244000052769 pathogen Species 0.000 abstract 1
230000001717 pathogenic effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1
238000011477 surgical intervention Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Polymers & Plastics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Food Science & Technology (AREA)
Animal Husbandry (AREA)
Birds (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Pediatric Medicine (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Orthopedics, Nursing, And Contraception (AREA)

AT02789898T 2002-11-26 2002-11-26 Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen ATE544354T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2002/037948 WO2004047778A1 (en)	2002-11-26	2002-11-26	Materials and methods for preventing and treating microbe-mediated epithelial disorders

Publications (1)

Publication Number	Publication Date
ATE544354T1 true ATE544354T1 (de)	2012-02-15

Family

ID=32391449

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02789898T ATE544354T1 (de)	2002-11-26	2002-11-26	Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen

Country Status (13)

Country	Link
US (3)	US20060198817A1 (de)
EP (1)	EP1567117B1 (de)
JP (1)	JP5271475B2 (de)
KR (1)	KR101087412B1 (de)
CN (1)	CN100536836C (de)
AT (1)	ATE544354T1 (de)
AU (1)	AU2002352938B8 (de)
BR (1)	BR0215954A (de)
CA (1)	CA2507018C (de)
DK (1)	DK1567117T3 (de)
ES (1)	ES2381998T3 (de)
PT (1)	PT1567117E (de)
WO (1)	WO2004047778A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007533755A (ja) *	2004-04-20	2007-11-22	ザユニヴァーシティオヴシカゴ	高分子量ｐｅｇ様化合物を含む治療薬送達システム
GB2421908A (en) *	2004-12-23	2006-07-12	Univ College London Hospitals	Medicament for treatment of inflammatory diseases
RU2365376C2 (ru) *	2005-05-23	2009-08-27	Владимир Александрович Малыгин	Набор для лечения дисбактериоза и способ лечения
AU2006255274A1 (en) *	2005-06-03	2006-12-14	The University Of Chicago	Modulation of microbial pathogen-host cell interactions
US20090186949A1 (en) *	2006-02-28	2009-07-23	The University Of Chicago	Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds
GB0612748D0 (en) *	2006-06-27	2006-08-09	Univ College London Hospitals	Treatment and/or prevention of inflammatory lung disease
US8663927B2 (en) *	2007-09-10	2014-03-04	University Of Kentucky Research Foundation	Systems and methods for diagnosis and monitoring of bacteria-related conditions
MX2011009988A (es) *	2009-03-23	2011-11-18	Univ Chicago	Metodos para la prevencion y el tratamiento de trastornos epiteliales inducidos por radiaciones.
EP2624823A4 (de)	2010-09-23	2016-08-03	Inflammagen	Verabreichung von serinproteasehemmern in den magen
NZ611807A (en)	2010-12-31	2015-02-27	Abbott Lab	Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
ES2804258T3 (es)	2010-12-31	2021-02-05	Abbott Lab	Procedimientos para reducir la incidencia de estrés oxidativo usando oligosacáridos de leche humana, vitamina C y agentes antiinflamatorios
US20140057993A1 (en) *	2011-04-27	2014-02-27	Northshore University Healthsystem	Prophylaxis and Treatment of Enteropathogenic Bacterial Infection
DK2734210T3 (en)	2011-07-22	2018-01-22	Abbott Lab	GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
US10639319B2 (en)	2011-08-29	2020-05-05	Abbott Laboratories	Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
BR112014006175B1 (pt) *	2011-09-16	2020-02-11	Ucb Pharma S.A.	Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
CN103520202B (zh) *	2012-07-02	2015-09-02	舒泰神（北京）生物制药股份有限公司	用于通便和清肠的药物组合物
US10045949B2 (en) *	2013-03-15	2018-08-14	Midway Pharmaceuticals, Inc	Managing osteoporosis with HMW PEG
ITPD20130133A1 (it) *	2013-05-14	2014-11-15	Sanypet S P A	Prodotto per l'alimentazione di cani affetti da disturbi infiammatori dell'intestino
CA2942358C (en)	2014-03-25	2023-03-28	Leading BioSciences, Inc.	Compositions for the treatment of autodigestion
WO2018064536A1 (en) *	2016-09-30	2018-04-05	The University Of Chicago	Phosphorylated tri-block copolymers with pathogen virulence-suppressing properties
CN109637293B (zh) *	2019-02-16	2020-11-24	哈尔滨学院	一种用于蒲丰投针实验的数学概率演示装置
EP3791885A1 (de) *	2019-09-13	2021-03-17	Consejo Superior de Investigaciones Cientificas (CSIC)	Polyethylenglykol zur verwendung in der prävention von abdominalen entzündungserkrankungen und/oder damit verbundenen erkrankungen
CN115531364B (zh) *	2021-06-30	2024-02-23	中国科学技术大学	预防或治疗轮状病毒感染的微生物代谢物制剂及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3487150A (en) *	1965-10-23	1969-12-30	Cornell Res Foundation Inc	Dextran sulphate treatment of peptic ulcers
NL154598B (nl) *	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) *	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en) *	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en) *	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) *	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4837008A (en) *	1985-04-09	1989-06-06	Peroxydent Group	Periodontal composition and method
US4659572A (en) *	1985-04-15	1987-04-21	Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence	Burn wound dressing material
USH1198H (en) *	1985-04-26	1993-06-01	Cetus Corporation	Pseudomonas aeruginosa type-specific human monoclonal antibodies, their preparation and use
NZ218499A (en) *	1985-12-10	1990-04-26	Genetic Systems Corp	Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4977137B1 (en) *	1987-06-03	1994-06-28	Baylor College Medicine	Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5661177A (en) *	1988-11-09	1997-08-26	Chimie Et Biologie	Zinc cysteate its preparation and uses in pharmacy and cosmetology
SE465109B (sv)	1989-10-30	1991-07-29	Bengt Andersson	Antibakteriell komposition
US5169627A (en) *	1991-10-28	1992-12-08	Mount Sinai School Of Medicine Of The City University Of New York	Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
US5409903A (en) *	1992-02-18	1995-04-25	Urecap Corporation	Method and compositions for the treatment of H. pylori and dermatitis
US5350770A (en) *	1992-07-28	1994-09-27	Elford Howard L	Therapeutic process for the treatment of septic shock
PH30929A (en) *	1992-09-03	1997-12-23	Janssen Pharmaceutica Nv	Beads having a core coated with an antifungal and a polymer.
DK17093D0 (da) *	1993-02-15	1993-02-15	Lyfjathroun H F	Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US6074671A (en) *	1993-10-01	2000-06-13	Legere Pharmaceuticals, Ltd.	Method of using lectins for contraception and prophylaxis against diseases transmittable by sexual contact and condom containing lectins
US6126933A (en) *	1995-06-27	2000-10-03	Genetics Institute	Methods of treating inflammatory bowel diseases by administering IL-11
US5908621A (en) *	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
US6017334A (en)	1996-10-03	2000-01-25	Board Of Regents, The University Of Texas System	Modified surfaces resistant to bacterial colonization
EP0973384A4 (de) *	1997-02-13	2004-10-13	Sky High Llc	Organkonservierungslösung
CA2292536A1 (en) *	1997-06-03	1998-12-10	Ganeden Biotech, Inc.	Probiotic lactic acid bacterium to treat bacterial infections associated with sids
AU9027298A (en) *	1997-08-20	1999-03-08	Lxr Biotechnology Inc.	Compositions containing polyethylene glycol and uses thereof
CN1264837C (zh) *	1997-09-15	2006-07-19	普罗克特和甘保尔公司	喹诺酮抗微生物剂、其组合物和应用
ATE245444T1 (de) *	1998-02-09	2003-08-15	Enzon Pharmaceuticals Inc	Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
JP3926626B2 (ja)	1999-08-18	2007-06-06	キム・ホヨン	免疫学的寛容−誘導物質
WO2001017560A1 (en)	1999-09-10	2001-03-15	Children's Medical Center Corporation	Method for treating and preventing bacterial infection
US6733781B2 (en) *	2000-12-06	2004-05-11	Wyeth	Fast dissolving tablet
CN1491676A (zh) *	2002-10-22	2004-04-28	刘小兵	经皮式(或口服式)避孕堕胎杀菌组合物

2002
- 2002-11-26 AT AT02789898T patent/ATE544354T1/de active
- 2002-11-26 US US10/535,918 patent/US20060198817A1/en not_active Abandoned
- 2002-11-26 KR KR1020057009411A patent/KR101087412B1/ko not_active Expired - Fee Related
- 2002-11-26 AU AU2002352938A patent/AU2002352938B8/en not_active Ceased
- 2002-11-26 PT PT02789898T patent/PT1567117E/pt unknown
- 2002-11-26 BR BR0215954-6A patent/BR0215954A/pt not_active Application Discontinuation
- 2002-11-26 WO PCT/US2002/037948 patent/WO2004047778A1/en not_active Ceased
- 2002-11-26 CA CA2507018A patent/CA2507018C/en not_active Expired - Fee Related
- 2002-11-26 JP JP2004555237A patent/JP5271475B2/ja not_active Expired - Fee Related
- 2002-11-26 DK DK02789898.0T patent/DK1567117T3/da active
- 2002-11-26 EP EP02789898A patent/EP1567117B1/de not_active Expired - Lifetime
- 2002-11-26 CN CNB028299604A patent/CN100536836C/zh not_active Expired - Fee Related
- 2002-11-26 ES ES02789898T patent/ES2381998T3/es not_active Expired - Lifetime
2015
- 2015-11-09 US US14/936,088 patent/US9549946B2/en not_active Expired - Fee Related
2016
- 2016-12-13 US US15/377,568 patent/US20170281668A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US9549946B2 (en)	2017-01-24
EP1567117A4 (de)	2009-07-08
AU2002352938B2 (en)	2009-09-10
JP5271475B2 (ja)	2013-08-21
KR101087412B1 (ko)	2011-11-25
ES2381998T3 (es)	2012-06-04
WO2004047778A1 (en)	2004-06-10
JP2006515837A (ja)	2006-06-08
US20160129038A1 (en)	2016-05-12
CN100536836C (zh)	2009-09-09
BR0215954A (pt)	2005-09-13
PT1567117E (pt)	2012-05-09
CA2507018C (en)	2014-03-25
CN1697644A (zh)	2005-11-16
AU2002352938B8 (en)	2009-10-08
DK1567117T3 (da)	2012-05-21
US20170281668A1 (en)	2017-10-05
US20060198817A1 (en)	2006-09-07
EP1567117A1 (de)	2005-08-31
HK1081445A1 (zh)	2006-05-19
EP1567117B1 (de)	2012-02-08
KR20050115855A (ko)	2005-12-08
CA2507018A1 (en)	2004-06-10
AU2002352938A1 (en)	2004-06-18

Publication	Publication Date	Title
DK1567117T3 (da)	2012-05-21	Forebyggelse og behandling af mikrobe-medierede epitelsygdomme
TWI372061B (en)	2012-09-11	Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
MX2013006641A (es)	2013-11-04	Formulaciones gastricas y coloncas y metodos para elaborar y usar las mismas.
CY1115891T1 (el)	2017-01-25	Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος
EP1988910A4 (de)	2013-03-06	Acryloyloxyethylphosphorylcholin-haltige polymerkonjugate und ihre zubereitung
IL225192A (en)	2017-12-31	Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
UA104634C2 (xx)	2014-02-25	Пегильована l-аспарагіназа $пегилированная l-аспарагиназа
JP6417488B2 (ja)	2018-11-07	疼痛抑制用医薬組成物
EA201590835A1 (ru)	2015-11-30	Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
WO2009037583A3 (en)	2010-01-28	Compositions and methods for treatment and prevention of osteoarthritis
EP2358395A4 (de)	2013-11-20	Verfahren und formulierung zur verminderung der aggregation eines makromoleküls unter physiologischen bedingungen
BR112022018645A2 (pt)	2022-11-08	Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
UY27204A1 (es)	2002-09-30	Derivados de pieracina
WO2018005794A3 (en)	2018-02-08	Novel non-systemic tgr5 agonists
MX2024014216A (es)	2024-12-06	Compuestos aromaticos que contienen boro y analogos de insulina relacionados
WO2006073430A3 (en)	2006-12-07	Therapeutic delivery system comprising a high molecular weight peg-like compound
BR112015011294A8 (pt)	2019-10-22	nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas
ATE285773T1 (de)	2005-01-15	Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE602004006024D1 (de)	2007-05-31	Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
FI3870233T3 (fi)	2024-02-07	Paklitakseli-Hyaluronihapon konjugaatti käytettäväksi ei-lihasinvasiivisen virtsarakon syövän hoidossa
WO2006089120A3 (en)	2006-11-23	Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
BR112012000410B8 (pt)	2020-12-08	uso de benzidamina ou dos sais de adição de ácido, e, composição farmacêutica
ATE477820T1 (de)	2010-09-15	Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
BRPI0405520A (pt)	2006-06-13	novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação
ATE522537T1 (de)	2011-09-15	(e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis